European patient engagement in critical condition

Thursday, October 15, 2015

Western Europe boasts one of the largest and most active markets for clinical trials. Indeed, more than one in five active clinical investigators is based in Western Europe, and the growth in sponsor spending there now outpaces that in the U.S.

[Read More]

EMA fast-tracks antidote to Pradaxa

Monday, September 28, 2015

The EMA has recommended granting a marketing authorization, following Accelerated Assessment, for Praxbind (idarucizumab) as a specific antidote to the anticoagulant medicine Pradaxa (dabigatran etexilate), when rapid reversal of its effect is required. Praxbind is to be used when a patient taking Pradaxa needs to undergo an emergency surgery or when life-threatening or uncontrolled bleeding occurs.

[Read More]

Venn Life Sciences to acquire Kinesis

Friday, September 25, 2015

Venn Life Sciences, a European CRO, has entered into an agreement to acquire the entire issued share capital of Kinesis Pharma, a Netherlands-based provider of specialist consultancy services around the chemical-pharmaceutical, nonclinical and early clinical development of drug products, for a total maximum consideration of up to $7.3 million (€6.5 million).

[Read More]

Report: Cancer deaths hitting U.K. in wallet

Tuesday, September 15, 2015

A new report says the difference in cancer survival rates between England and rest of Europe has stood at about 10% for the past 20 years, and closing that divide would add about £117 million ($180 million) a year to the U.K. economy.

[Read More]